Kosin Med J.  2023 Mar;38(1):1-3. 10.7180/kmj.23.108.

What is the effect of deferred laser treatment on reactivated retinopathy of prematurity after anti-VEGF injection?

• Jang JH

• KMID: 2540755
• DOI: http://doi.org/10.7180/kmj.23.108

Reference

References

1. Hartnett ME. Advances in understanding and management of retinopathy of prematurity. Surv Ophthalmol. 2017; 62:257–76.

2. Dai C, Webster KA, Bhatt A, Tian H, Su G, Li W. Concurrent physiological and pathological angiogenesis in retinopathy of prematurity and emerging therapies. Int J Mol Sci. 2021; 22:4809.

3. Tsai AS, Chou HD, Ling XC, Al-Khaled T, Valikodath N, Cole E, et al. Assessment and management of retinopathy of prematurity in the era of anti-vascular endothelial growth factor (VEGF). Prog Retin Eye Res. 2022; 88:101018.

4. Wang SD, Zhang GM; Shenzhen Screening for Retinopathy of Prematurity Cooperative Group. Laser therapy versus intravitreal injection of anti-VEGF agents in monotherapy of ROP: a meta-analysis. Int J Ophthalmol. 2020; 13:806–15.

5. Linghu D, Cheng Y, Zhu X, Deng X, Yin H, Jiang Y, et al. Comparison of intravitreal anti-VEGF agents with laser photocoagulation for retinopathy of prematurity of 1,627 eyes in China. Front Med (Lausanne). 2022; 9:911095.

6. Jang JH, Kang YK, Park HS, Kim K, Kim SS, Han JY, et al. Primary and additional treatment preference in aggressive retinopathy of prematurity and type 1 retinopathy of prematurity. BMJ Open Ophthalmol. 2023; 8:e001166.

7. Lee JS, Nam KY, Lee JE, Lee JE, Lee SJ. Revascularization of immature retinas with retinopathy of prematurity using combination therapy of deferred laser treatment after a single intravitreal bevacizumab injection. Kosin Med J. 2023; 38:28–35.

8. Toy BC, Schachar IH, Tan GS, Moshfeghi DM. Chronic vascular arrest as a predictor of bevacizumab treatment failure in retinopathy of prematurity. Ophthalmology. 2016; 123:2166–75.

9. Chen TA, Shields RA, Bodnar ZH, Callaway NF, Schachar IH, Moshfeghi DM. A spectrum of regression following intravitreal bevacizumab in retinopathy of prematurity. Am J Ophthalmol. 2019; 198:63–9.

10. Mintz-Hittner HA, Geloneck MM, Chuang AZ. Clinical management of recurrent retinopathy of prematurity after intravitreal bevacizumab monotherapy. Ophthalmology. 2016; 123:1845–55.

11. Valikodath NG, Chiang MF, Chan RV. Description and management of retinopathy of prematurity reactivation after intravitreal antivascular endothelial growth factor therapy. Curr Opin Ophthalmol. 2021; 32:468–74.

12. Martinez-Castellanos MA, Gonzalez-H Leon A, Romo-Aguas JC, Gonzalez-Gonzalez LA. A proposal of an algorithm for the diagnosis and treatment of recurrence or treatment failure of retinopathy of prematurity after anti-VEGF therapy based on a large case series. Graefes Arch Clin Exp Ophthalmol. 2020; 258:767–72.

13. Garcia Gonzalez JM, Snyder L, Blair M, Rohr A, Shapiro M, Greenwald M. Prophylactic peripheral laser and fluorescein angiography after bevacizumab for retinopathy of prematurity. Retina. 2018; 38:764–72.